Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/33956
Full metadata record
DC FieldValueLanguage
dc.contributor.authorNoelle, Randolph J-
dc.contributor.authorLines, J Louise-
dc.contributor.authorLewis, Lionel D-
dc.contributor.authorMartell, Robert E-
dc.contributor.authorGuillaudeux, Thierry-
dc.contributor.authorLee, Sam W-
dc.contributor.authorMahoney, Kathleen M-
dc.contributor.authorVesely, Matthew D-
dc.contributor.authorBoyd-Kirkup, Jerome-
dc.contributor.authorNambiar, Dhanya K-
dc.contributor.authorScott, Andrew M-
dc.date2023-
dc.date.accessioned2023-10-11T06:21:18Z-
dc.date.available2023-10-11T06:21:18Z-
dc.date.issued2023-
dc.identifier.citationFrontiers in Oncology 2023; 13en_US
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/33956-
dc.description.abstractImmune checkpoints limit the activation of the immune system and serve an important homeostatic function but can also restrict immune responses against tumors. Inhibition of specific immune checkpoint proteins such as the B7:CD28 family members programmed cell death protein-1 (PD-1) and cytotoxic T-lymphocyte antigen-4 (CTLA-4) has transformed the treatment of various cancers by promoting the anti-tumor activation of immune cells. In contrast to these effects, the V-domain immunoglobulin suppressor of T-cell activation (VISTA) regulates the steady state of the resting immune system and promotes homeostasis by mechanisms distinct from PD-1 and CTLA-4. The effects of VISTA blockade have been shown to include a decrease in myeloid suppression coupled with proinflammatory changes by mechanisms that are separate and distinct from other immune checkpoint proteins; in some preclinical studies these immune effects appear synergistic. Given the potential benefits of VISTA blockade in the context of cancer therapy, the second Annual VISTA Symposium was convened virtually on September 23, 2022, to review new research from investigators and immuno-oncology experts. Discussions in the meeting extended the knowledge of VISTA biology and the effects of VISTA inhibition, particularly on cells of the myeloid lineage and resting T cells, as three candidate anti-VISTA antibodies are in, or nearing, clinical development.en_US
dc.language.isoeng-
dc.subjectPD-1en_US
dc.subjectVISTAen_US
dc.subjectcheckpoint inhibitors (ICIs)en_US
dc.subjectimmune checkpointen_US
dc.subjectimmuno-oncology (IO)en_US
dc.subjectimmunotherapyen_US
dc.subjectmyeloiden_US
dc.titleClinical and research updates on the VISTA immune checkpoint: immuno-oncology themes and highlights.en_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleFrontiers in Oncologyen_US
dc.identifier.affiliationImmuNext Inc., Lebanon, NH, United States.;Department of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Hanover, NH, United States.en_US
dc.identifier.affiliationDepartment of Microbiology and Immunology, Dartmouth Cancer Center, Geisel School of Medicine at Dartmouth, Hanover, NH, United States.en_US
dc.identifier.affiliationSection of Clinical Pharmacology, Department of Medicine, Geisel School of Medicine at Dartmouth and Dartmouth Cancer Center, Hanover, NH, United States.en_US
dc.identifier.affiliationCuris, Inc., Lexington, MA, United States.;Division of Hematology/Oncology, Tufts Medical Center, Boston, MA, United States.en_US
dc.identifier.affiliationKineta Inc., Seattle, WA, United States.en_US
dc.identifier.affiliationYale University School of Medicine, New Haven, CT, United States.en_US
dc.identifier.affiliationDepartment of Medical, Division of Medical Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States.;Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States.en_US
dc.identifier.affiliationDepartment of Dermatology, Yale School of Medicine, New Haven, CT, United States.en_US
dc.identifier.affiliationHummingbird Bioscience, Houston, TX, United States.en_US
dc.identifier.affiliationDepartment of Radiation Oncology, Stanford School of Medicine, Stanford, CA, United States.en_US
dc.identifier.affiliationOlivia Newton-John Cancer Research Institute and School of Cancer Medicine, La Trobe University, Melbourne, VIC, Australia.en_US
dc.identifier.affiliationMolecular Imaging and Therapyen_US
dc.identifier.doi10.3389/fonc.2023.1225081en_US
dc.type.contentTexten_US
dc.identifier.pubmedid37795437-
dc.description.volume13-
dc.description.startpage1225081-
item.grantfulltextnone-
item.openairetypeJournal Article-
item.languageiso639-1en-
item.fulltextNo Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
crisitem.author.deptMolecular Imaging and Therapy-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

26
checked on Nov 21, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.